Gastritis News and Research

RSS

Gastritis is not a single disease, but several different conditions that all have inflammation of the stomach lining. Gastritis can be caused by drinking too much alcohol, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen, or infection with bacteria such as Helicobacter pylori (H. pylori). Sometimes gastritis develops after major surgery, traumatic injury, burns, or severe infections. Certain diseases, such as pernicious anemia, autoimmune disorders, and chronic bile reflux, can cause gastritis as well.

New animal model may help study immune responses to H. pylori infection

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have developed a new large animal model to study how the immune system interacts with the stomach bacterium Helicobacter pylori, the leading cause of peptic ulcer disease.

26 Sep 2013

Natural eradication of Helicobacter from human populations

Gut-dwelling bacteria are attracting increasing attention, particularly those associated with human diseases. Helicobacter pylori is found in the stomach of humans, where it may cause chronic gastritis and gastric ulcers, although the majority of infections are asymptomatic.

21 Sep 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Genetic loci associated with H pylori bacteria are linked to stomach cancer

Two genome-wide association studies and a subsequent meta-analysis have found that certain genetic variations are associated with susceptibility to Helicobacter pylori, a bacteria that is a major cause of gastritis and stomach ulcers and is linked to stomach cancer, findings that may help explain some of the observed variation in individual risk for H pylori infection, according to a study in the May 8 issue of JAMA.

8 May 2013

POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.

27 Mar 2013

Technique breathes new life into gastric cancer diagnosis

A nanomaterial breath test can accurately distinguish gastric cancer from benign stomach disorders, preliminary results show.

7 Mar 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Case Western Reserve receives $220,000 grant to study gastric cancers

The Case Western Reserve University School of Medicine has received a $220,000 grant from the DeGregorio Family Foundation to study gastric cancers, which remain among the most deadly forms of disease.

11 Feb 2013

Virginia Tech researchers reveal how 'bad' gut bacteria may help control diabetes

A stomach bacterium believed to cause health problems such as gastritis, ulcers, and gastric cancer may play a dual role by balancing the stomach's ecosystem and controlling body weight and glucose tolerance, according to immunologists at the Virginia Bioinformatics Institute of Virginia Tech.

10 Feb 2013

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease.

10 Feb 2013

mTorc1 promotes growth of inflammation-associated colon and gastric cancers

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

18 Jan 2013

H. pylori may protect against stroke and some cancers

A new study by NYU School of Medicine researchers reveals that an especially virulent strain of the gut bacterium Helicobacter pylori (H. pylori) isn't implicated in the overall death rate of the U.S. population, and may even protect against stroke and some cancers.

10 Jan 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

H. pylori colonic neoplasm link confirmed

Helicobacter pylori gastritis is significantly associated with colonic neoplasms, show the results of one of the largest studies of the association to date.

6 Dec 2012

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.

6 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Scoring system identifies appendicitis in pediatric acute abdomen pain

Using a pediatric appendicitis score may help to identify true cases of appendicitis among children who present to emergency departments with acute abdominal pain, researchers report.

26 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration.

25 May 2012